Dr Reddy’s is delaying semaglutide supplies after identifying an issue with the drug’s active ingredient quality, according to reports from Indian business outlets. The company says it has found certain batches of semaglutide to be out of specification. Dr Reddy’s indicates it is investigating the root cause of the deviation and is taking corrective measures to ensure product quality. The company’s actions are intended to prevent further distribution of affected batches while the investigation is ongoing. Coverage of the matter also notes that the delay is tied specifically to the active ingredient rather than to a broader manufacturing stoppage. The company has not provided, in the available reporting, detailed information on the scope of the affected lots, the duration of the supply disruption, or the specific regulatory or inspection findings that led to the reassessment of batches. The company’s next steps are described as focused on identifying why the batches did not meet required specifications and implementing measures to restore compliance before resuming supply.